Opus Genetics (IRD) Competitors $1.25 -0.03 (-1.95%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. OCGN, GLUE, SCPH, ACB, FHTX, CAPR, FDMT, LFCR, TVRD, and MREOShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), scPharmaceuticals (SCPH), Aurora Cannabis (ACB), Foghorn Therapeutics (FHTX), Capricor Therapeutics (CAPR), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), Tvardi Therapeutics (TVRD), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Ocugen Monte Rosa Therapeutics scPharmaceuticals Aurora Cannabis Foghorn Therapeutics Capricor Therapeutics 4D Molecular Therapeutics Lifecore Biomedical Tvardi Therapeutics Mereo BioPharma Group Opus Genetics (NASDAQ:IRD) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Which has more risk and volatility, IRD or OCGN? Opus Genetics has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.15, meaning that its share price is 315% more volatile than the S&P 500. Do institutionals and insiders believe in IRD or OCGN? 15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by insiders. Comparatively, 4.4% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, IRD or OCGN? Ocugen has lower revenue, but higher earnings than Opus Genetics. Ocugen is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M6.84-$57.53M-$1.92-0.65Ocugen$4.05M73.98-$54.05M-$0.20-5.13 Is IRD or OCGN more profitable? Opus Genetics has a net margin of -377.89% compared to Ocugen's net margin of -1,197.71%. Ocugen's return on equity of -255.25% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-377.89% -384.33% -148.90% Ocugen -1,197.71%-255.25%-86.79% Do analysts rate IRD or OCGN? Opus Genetics currently has a consensus price target of $7.33, indicating a potential upside of 484.33%. Ocugen has a consensus price target of $6.00, indicating a potential upside of 485.37%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Opus Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IRD or OCGN? In the previous week, Opus Genetics had 3 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Opus Genetics and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.66 beat Opus Genetics' score of 0.49 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOcugen beats Opus Genetics on 8 of the 14 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.13M$3.16B$5.77B$9.91BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-0.6521.1175.8026.59Price / Sales6.84471.44555.58120.92Price / CashN/A45.1137.1158.92Price / Book5.989.8811.446.06Net Income-$57.53M-$53.47M$3.29B$266.42M7 Day Performance2.87%2.09%0.41%-0.17%1 Month Performance13.06%7.82%6.69%3.69%1 Year PerformanceN/A12.94%59.20%23.46% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.9304 of 5 stars$1.26-2.0%$7.33+484.3%N/A$75.13M$10.99M-0.6514News CoveragePositive NewsGap UpOCGNOcugen1.2202 of 5 stars$1.02-0.5%$6.00+491.1%-11.2%$296.68M$4.05M-5.0780GLUEMonte Rosa Therapeutics2.914 of 5 stars$4.89+1.8%$15.33+213.7%-12.8%$296.44M$177.99M13.6090News CoveragePositive NewsSCPHscPharmaceuticals4.118 of 5 stars$5.52+0.3%$12.00+117.6%+9.6%$293.95M$36.33M-3.0530Short Interest ↑High Trading VolumeACBAurora Cannabis0.1467 of 5 stars$5.16-4.9%N/A-14.8%$291.17M$246.72M-27.151,130FHTXFoghorn Therapeutics2.977 of 5 stars$5.06-0.1%$10.67+111.0%-32.4%$287.74M$22.60M-4.28120Positive NewsCAPRCapricor Therapeutics2.8986 of 5 stars$6.26-0.3%$22.56+260.4%+36.6%$286.21M$22.27M-3.82101FDMT4D Molecular Therapeutics2.7708 of 5 stars$6.11-0.9%$30.40+397.9%-57.7%$285.57M$40K-1.73120News CoverageGap DownLFCRLifecore Biomedical0.6954 of 5 stars$7.53-1.1%$8.00+6.3%+88.2%$283.01M$128.87M-5.77690Trending NewsAnalyst ForecastAnalyst RevisionTVRDTvardi TherapeuticsN/A$30.00+0.3%$64.25+114.2%N/A$281.40M$7.14M0.0080Positive NewsGap UpMREOMereo BioPharma Group2.5032 of 5 stars$1.77+3.2%$7.40+319.3%-60.2%$280.64M$10M-25.2140 Related Companies and Tools Related Companies Ocugen Alternatives Monte Rosa Therapeutics Alternatives scPharmaceuticals Alternatives Aurora Cannabis Alternatives Foghorn Therapeutics Alternatives Capricor Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Lifecore Biomedical Alternatives Tvardi Therapeutics Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts